Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6367507 | 0.86 | GAA (0.31) | GAAMGAMSIMGAM2KDM4E | |
| SCHEMBL597825 | 0.85 | ALDH1A1 (0.44) | ALDH1A1LMNAGAATSHRKMT2A | |
| SCHEMBL2554064 | 0.84 | ALDH1A1 (0.30) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL13772646 | 0.80 | MGAM (0.33) | GAAMGAMSIMGAM2KDM4E | |
| SCHEMBL598112 | 0.79 | ALDH1A1 (0.44) | ALDH1A1LMNAGAATSHRKMT2A | |
| SCHEMBL4577419 | 0.77 | GAA (0.44) | ALDH1A1LMNAHSD17B10GAAMGAM | |
| SCHEMBL1747000 | 0.77 | ALDH1A1 (0.47) | ALDH1A1LMNAGAATSHRKMT2A | |
| SCHEMBL2544830 | 0.76 | ACHE (0.31) | — | |
| SCHEMBL12956510 | 0.76 | ALDH1A1 (0.36) | ALDH1A1LMNAGAATSHRKMT2A | |
| SCHEMBL6099264 | 0.76 | LMNA (0.44) | ALDH1A1LMNAGAAMGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059735-A1 | Cyclic amino acid derivatives useful as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2005-03-17 | — | — | US | claimed |
| US-20030216469-A1 | Cyclic amino acid derivatives useful as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-11-20 | — | — | US | claimed |
| EP-1284960-A1 | CYCLIC AMINO ACID DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2003-02-26 | — | — | EP | claimed |
| WO-2001090052-A1 | CYCLIC AMINO ACID DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2001-11-29 | — | — | WO | claimed |
| US-20050059735-A1 | Cyclic amino acid derivatives useful as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2005-03-17 | — | — | US | disclosed |
| EP-1404310-A4 | ORALLY ADMINISTERED DOSAGE FORMS OF GABA ANALOG PRODRUGS HAVING REDUCED TOXICITY | XENOPORT INC (US) | 2005-01-12 | — | — | EP | disclosed |
| US-6833140-B2 | Extended release of gamma-aminobutyric acid (GABA); for treatment or prevention of epilepsy, depression, anxiety, psychosis, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, panic, and pain | XENOPORT, INC. | 2004-12-21 | — | — | US | disclosed |
| US-20040198820-A1 | Orally administered dosage forms of gaba analog prodrugs having reduced toxicity | XENOPORT, INC. | 2004-10-07 | — | — | US | disclosed |
| EP-1404310-A1 | ORALLY ADMINISTERED DOSAGE FORMS OF GABA ANALOG PRODRUGS HAVING REDUCED TOXICITY | Xenoport, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030216469-A1 | Cyclic amino acid derivatives useful as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-11-20 | — | — | US | disclosed |
| US-20030083382-A1 | Orally administered dosage forms of GABA analog prodrugs having reduced toxicity | ARBOR PHARMACEUTICALS, LLC | 2003-05-01 | — | — | US | disclosed |
| EP-1284960-A1 | CYCLIC AMINO ACID DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2003-02-26 | — | — | EP | disclosed |
| WO-2002100392-A1 | ORALLY ADMINISTERED DOSAGE FORMS OF GABA ANALOG PRODRUGS HAVING REDUCED TOXICITY | XENOPORT, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2001090052-A1 | CYCLIC AMINO ACID DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198820-A1 | Orally administered dosage forms of gaba analog prodrugs having reduced toxicity | GABRB1, GABRB2, GABRB3 | ALDH1A1 37/4885LMNA 3884/4885HSD17B10 429/4885 |
| US-20050059735-A1 | Cyclic amino acid derivatives useful as pharmaceutical agents | QPCT, ARGLU1, PNISR | ALDH1A1 3285/4885LMNA 783/4885HSD17B10 4562/4885 |
| US-20030216469-A1 | Cyclic amino acid derivatives useful as pharmaceutical agents | QPCT, ARGLU1, QPCTL | ALDH1A1 3091/4885LMNA 653/4885HSD17B10 4620/4885 |
| US-20030083382-A1 | Orally administered dosage forms of GABA analog prodrugs having reduced toxicity | GABRB1, GABRB2, GABRB3 | ALDH1A1 37/4885LMNA 3884/4885HSD17B10 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.